KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) EBT (2016 - 2025)

Fulgent Genetics' EBT history spans 11 years, with the latest figure at $32.5 million for Q4 2025.

  • For Q4 2025, EBT fell 16.21% year-over-year to $32.5 million; the TTM value through Dec 2025 reached -$8.3 million, down 60.47%, while the annual FY2025 figure was -$8.3 million, 60.72% down from the prior year.
  • EBT for Q4 2025 was $32.5 million at Fulgent Genetics, up from -$7.5 million in the prior quarter.
  • Across five years, EBT topped out at $267.2 million in Q1 2021 and bottomed at -$222.9 million in Q4 2022.
  • The 5-year median for EBT is -$2.9 million (2022), against an average of $24.2 million.
  • The largest annual shift saw EBT soared 16071.55% in 2021 before it crashed 370.15% in 2024.
  • A 5-year view of EBT shows it stood at $150.8 million in 2021, then crashed by 247.77% to -$222.9 million in 2022, then soared by 34.85% to -$145.2 million in 2023, then soared by 126.7% to $38.8 million in 2024, then dropped by 16.21% to $32.5 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's EBT are $32.5 million (Q4 2025), -$7.5 million (Q3 2025), and -$21.5 million (Q2 2025).